Welcome to the Stocktwits Top 25 Newsletter this week!

The Stocktwits Top 25 reports the 25 best-performing stocks in the S&P 500, Nasdaq 100, and Russell 2000 year to date and tracks their performances over time. To help you understand this data further, check out our FAQ page, and feel free to reach out if you have questions!

Bearish 🐻 | Bullish 🐮 | It’s Complicated 😵‍💫

Here are the Stocktwits Top 25 Lists for this week:

You may not have gotten into SpaceX early, but the space-investing story is far from over.

Record launches, falling costs, government contracts and new technologies are turning space into a commercial market. That growth is creating opportunities across satellites, defense, communications, data and in-space infrastructure.

This free report 7 Best Space Stocks to Own in 2026 reveals seven publicly traded companies positioned across this expanding economy. It explains how each business makes money, what could move its stock and which risks investors should understand.

SpaceX captured Wall Street’s attention. Now see which seven space stocks could benefit from what comes next.

See the 7 Stocks

Biotech and semiconductors dominated the small-cap leaderboard, but the easy part of these runs is over.

$IOVA ( ▼ 0.11% ) : Iovance, 11 to 6: Raised 2026 revenue guidance to $410M-$420M as Amtagvi demand and treatment-center growth accelerated. Shares held sixth despite a flat week. Risk: The forecast assumes manufacturing and patient throughput keep pace across roughly 100 authorized centers.

$CDNA ( ▲ 1.39% ) : CareDx, 20 to 15: Preliminary 2027 Medicare rates kept AlloMap at $3,240 and lifted AlloSure about 3%, supporting a stock already up 256% this year. Risk: CMS will not finalize the fee schedule until November, and the Naveris acquisition still needs a clean integration.

$MXL ( ▲ 14.99% ) : MaxLinear, 2 to 1: A 15% weekly jump put MaxLinear atop the board as its data-center and infrastructure products kept attracting buyers. Risk: After a 508% yearly gain, the October 22 earnings report has to justify expectations for faster growth and wider margins.

$KOD ( ▼ 4.07% ) : Kodiak Sciences, new at 19: Positive Phase 3 DAYBREAK data moved Zenkuda closer to a wet-AMD filing, but the stock lost 4.1% this week. Risk: Regeneron and Roche already own the market, and Zenkuda’s dosing durability still has to hold up.

$OPTX ( ▲ 12.7% ) : Syntec Optics, new at 23: Shares added 12.7% this week as a Space Force optics order strengthened the defense-and-space backlog story. Risk: The order value was not disclosed, and a recent $20M raise at $7 keeps dilution and backlog conversion in focus.

Next week’s swing factor: FOMC minutes arrive Wednesday at 2 p.m. ET. Semiconductors and biotech have plenty riding on whether the Fed’s September hike still looks repeatable.

Want to see some change? Respond to this email and reach me, Kevin Travers, with feedback. Follow me on Stocktwits. Send me charts and ideas! Refer a friend for this quarter’s edition of The RIP Forecast 😎

Securities Disclaimer: STOCKTWITS IS NOT A TAX ADVISOR, BROKER, FINANCIAL ADVISOR OR INVESTMENT ADVISOR. THE SERVICE IS NOT INTENDED TO PROVIDE TAX, LEGAL, FINANCIAL OR INVESTMENT ADVICE, AND NOTHING ON THE SERVICE SHOULD BE CONSTRUED AS AN OFFER TO SELL, A SOLICITATION OF AN OFFER TO BUY, OR A RECOMMENDATION FOR ANY SECURITY. Trading in such securities can result in immediate and substantial losses of the capital invested. You should only invest risk capital, and not capital required for other purposes. You alone are solely responsible for determining whether any investment, security or strategy, or any other product or service, is appropriate or suitable for you based on your investment objectives and personal and financial situation. You should also consult an attorney or tax professional regarding your specific legal or tax situation. The Content is to be used for informational and entertainment purposes only and the Service does not provide investment advice for any individual. Stocktwits, its affiliates and partners specifically disclaim any and all liability or loss arising out of any action taken in reliance on Content, including but not limited to market value or other loss on the sale or purchase of any company, property, product, service, security, instrument, or any other matter. You understand that an investment in any security is subject to a number of risks, and that discussions of any security published on the Service will not contain a list or description of relevant risk factors. In addition, please note that some of the stocks about which Content is published on the Service have a low market capitalization and/or insufficient public float. Such stocks are subject to more risk than stocks of larger companies, including greater volatility, lower liquidity and less publicly available information. Read the full terms & conditions here. 🔍

Author Disclosure: The author of this newsletter does not hold positions in any of the securities or assets mentioned. 📋